secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensus Healthcare, Inc. (SRTS)
CIK:        0001494891
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001213900-22-024232
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensus Healthcare Q1 revenue $10.3M (+237% YoY); net income $0.97/share; launches new product, share buyback
--------------------------------------------------------------------------------

- Revenue $10.3M, up 237% YoY; net income $16.1M ($0.97 diluted) vs net loss $1.1M.
- Adjusted EBITDA $16.9M vs $(0.8M); gross margin expanded to 69.1% from 51.6%.
- Sold non-core asset for $15.0M cash, recorded $12.8M gain; launched TransDermal Infusion product.
- Board approved $3.0M share repurchase program; cash balance $32.8M.
- Affirms Q2 and FY 2022 profitability expectations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1494891/000121390022024232/0001213900-22-024232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1494891/000121390022024232/ea159369-8k_sensushealth.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-024232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer